Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15774303 | 1.00 | CA2 (0.47) | CA2CA1PPARAEPHX1TP53 | |
| SCHEMBL5007363 | 1.00 | CA2 (0.47) | CA2CA1PPARAEPHX1TP53 | |
| SCHEMBL29178058 | 0.98 | CA2 (0.46) | CA2CA1PPARAEPHX1TP53 | |
| SCHEMBL11667830 | 0.98 | TP53 (0.45) | CA2CA1PPARAEPHX1TP53 | |
| SCHEMBL10807218 | 0.94 | CA2 (0.43) | CA2CA1PPARAEPHX1TP53 | |
| SCHEMBL27581208 | 0.89 | PPARA (0.54) | PPARA | |
| SCHEMBL22115555 | 0.88 | TP53 (0.51) | CA2CA1TP53 | |
| SCHEMBL28096531 | 0.85 | CA1 (0.39) | CA2CA1PPARAEPHX1TP53 | |
| SCHEMBL11145285 | 0.83 | GRIA1 (0.37) | GRIA1 | |
| SCHEMBL21518448 | 0.80 | CA2 (0.44) | CA2CA1PPARAEPHX1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0776668-B1 | Process for the removal of aromatic compounds from solutions | AVENTIS BEHRING GMBH (DE) | 2003-09-24 | — | — | EP | claimed |
| US-5883256-A | CLEANING FOR VIRAL AGENTS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | claimed |
| EP-0776668-B1 | Process for the removal of aromatic compounds from solutions | AVENTIS BEHRING GMBH (DE) | 2003-09-24 | — | — | EP | disclosed |
| EP-0722344-B1 | PROCESS FOR VIRUS DEACTIVATION IN THE PRESENCE OF A POLYETHER AND AN AGENS | BAXTER AG (AT) | 2002-01-16 | — | — | EP | disclosed |
| EP-1073425-A1 | FIBRINOGEN COATED DROPLETS OF LIQUID HYDROPHOBIC PHASES | THE UNIVERSITY OF CINCINNATI (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055314-A1 | FIBRINOGEN COATED DROPLETS OF LIQUID HYDROPHOBIC PHASES | UNIVERSITY OF CINCINNATI (US) | 1999-11-04 | — | — | WO | disclosed |
| EP-0602173-B1 | TOPICAL FIBRINOGEN COMPLEX | BAXTER INT (US) | 1999-05-26 | — | — | EP | disclosed |
| US-5883256-A | CLEANING FOR VIRAL AGENTS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | disclosed |
| US-5792835-A | COLLECTING A FRACTION FROM A CRYOPRECIPITATED BUFFERED SUSPENSION OF HUMAN PLASMA; ADSORPTION ON A LYSINE-BOUND CHROMATOGRAPHIC MATRIX; TREATING WITH A VIRICIDE; WOUND HEALING AGENTS | BAXTER INTERNATIONAL INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5770199-A | DEACTIVATING THE INFECTION VIRUS BY MIXING WITH A POLYETHER AND A CHAOTROPIC AGENT | IMMUNO AKTIENGESELLSCHAFT (AT) | 1998-06-23 | — | — | US | disclosed |
| US-5716645-A | POOLED PLASMA-DERIVED FIBRINOGEN CRYOPRECIPITATE FREE OF ANTIFIBRINOLYTIC AGENTS, NONHUMAN PROTEINS AND VIRUSES; HEMOSTATIC AGENTS, TENSILE STRENGTH | BAXTER INTERNATIONAL INC. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0197554-B1 | TREATMENT OF BIOLOGICAL AND PHARMACEUTICAL PRODUCTS ADSORBED ON A SOLID PHASE WITH VIRUS AND PYROGEN INACTIVATING AGENTS | Armour Pharmaceutical Company (US) | 1990-07-25 | — | — | EP | disclosed |
| EP-0050061-B2 | METHOD OF REDUCING UNDESIRABLE ACTIVITIES OF BIOLOGICAL AND PHARMACEUTICAL PRODUCTS | New York Blood Center, Inc. (US) | 1990-06-20 | — | — | EP | disclosed |
| EP-0286323-A2 | An ultrapurification process for factor VIII:C | BAXTER INTERNATIONAL INC. (a Delaware corporation) (US) | 1988-10-12 | — | — | EP | disclosed |
| US-4673733-A | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents | ARMOUR PHARMACEUTICAL COMPANY, A CORP OF DE | 1987-06-16 | — | — | US | disclosed |
| EP-0197554-A2 | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents | Armour Pharmaceutical Company (US) | 1986-10-15 | — | — | EP | disclosed |
| EP-0050061-B1 | METHOD OF REDUCING UNDESIRABLE ACTIVITIES OF BIOLOGICAL AND PHARMACEUTICAL PRODUCTS | New York Blood Center, Inc. (US) | 1985-12-11 | — | — | EP | disclosed |
| EP-0050061-A2 | Method of reducing undesirable activities of biological and pharmaceutical products | New York Blood Center, Inc. (US) | 1982-04-21 | — | — | EP | disclosed |
| US-4315919-A | AMPHIPHILE SOLUTION AND BILE ACID SALT USED ON PROTEINS | SHANBROM EDWARD | 1982-02-16 | — | — | US | disclosed |
| US-4314997-A | WITH SURFACTANT | SHANBROM EDWARD | 1982-02-09 | — | — | US | disclosed |